Table 3.
Acne event involvement and morphology (16-week placebo-controlled period)
| Parameter, n (%) | Patients with acne during the double-blind period | ||
|---|---|---|---|
| UPA 15 mg + TCS, n = 12 | UPA 30 mg + TCS, n = 18 | Placebo + TCS, n = 5 | |
| Areas of acne involvement | |||
| Face | 10 (83.3) | 17 (94.4) | 4 (80.0) |
| Trunk | 3 (25.0) | 5 (27.8) | 1 (20.0) |
| Extremities | 2 (16.7) | 2 (11.1) | 0 |
| Morphology for acne | |||
| Inflammatory papules | 10 (83.3) | 16 (88.9) | 5 (100) |
| Pustules | 5 (41.7) | 10 (55.6) | 4 (80.0) |
| Comedones | 4 (33.3) | 7 (38.9) | 1 (20.0) |
| Inflammatory nodules and cysts | 1 (8.3) | 1 (5.6) | 0 |
| Scarring | 0 | 0 | 0 |
TCS topical corticosteroids, TEAE treatment-emergent adverse event, UPA upadacitinib